Note: Impactiviti Daily is going to be published somewhat irregularly over the next couple of weeks, as we’re in the heart of “conference” season and I’m attending/speaking at several events over the next month. We’ll do our best to keep you updated!
TODAY’S NEWS
FDA approves Arzerra (from GSK) for last-ditch treatment of CLL (cancer)
Boehringer-Ingelheim gets additional approvals for Micardis, including a combo drug (Twynsta)
Vertex gets positive results for its experimental Hep C drug – but I bet this headline gets more traction.
RECOMMENDED
Product Launch Training. Impactiviti’s partner network includes top-notch developers of therapeutic and product training – on-line, print, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for brainstorming and recommendations.
PLUS
My review of last week’s Digital Pharma conference. It was, in some ways, a ground-breaking event.
Business buzz-jargon reaches a new height. You just can’t make this stuff up!
JUST FOR FUN
Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
